Cargando…
Neutralising antibodies in patients with multiple myeloma receiving maintenance therapy with interferon alpha 2b.
In a study of 29 patients who were receiving or had received interferon alpha 2b (IFN-alpha 2b) as maintenance therapy for multiple myeloma, antibodies were detected in 58% (17/29) of patients measured by a solid-phase enzyme-linked immunosorbent assay (ELISA). Only 7/17 patients who were positive f...
Autores principales: | Bell, J. B., Barfoot, R., Iveson, T., Powles, R. L., Millar, B. C. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1994
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2033398/ https://www.ncbi.nlm.nih.gov/pubmed/7917911 |
Ejemplares similares
-
Lymphocyte recovery and clinical response in multiple myeloma patients receiving interferon alpha 2 beta after intensive therapy.
por: Millar, B. C., et al.
Publicado: (1996) -
2',5'-Oligoadenylate synthetase levels in patients with multiple myeloma receiving maintenance therapy with interferon alpha 2b do not correlate with clinical response.
por: Millar, B. C., et al.
Publicado: (1995) -
The proliferation of multiple myeloma colonies (MY-CFUc) in vitro is independent of prognosis and is not associated with mutated N- or K-ras alleles in human bone marrow aspirates.
por: Millar, B. C., et al.
Publicado: (1995) -
Prevalence of neutralising antibodies to interferon-beta and clinical response in Chinese patients with relapsing multiple sclerosis
por: Lau, Alexander Y, et al.
Publicado: (2017) -
Mechanisms of Rhinovirus Neutralisation by Antibodies
por: Touabi, Lila, et al.
Publicado: (2021)